|
KR102205028B1
|
|
A binding molecules able to neutralize SARS-CoV-2
|
|
KR102229225B1
|
|
Binding Molecules Binding To A Spike Protein Of SARS-CoV-2 For Diagnosis Of COVID-19
|
|
WO2021040440A1
|
|
Pharmaceutical composition for treating or preventing nonalcoholic steatohepatitis (nash)
|
|
KR20210010412A
|
|
The immunogenic composition comprising multivalent pneumococcal polysaccharide-protein conjugate
|
|
UY38595A
|
|
METHODS FOR THE TREATMENT OF TNFA-RELATED DISEASES
|
|
KR102189376B1
|
|
Composition For Anti-inflammation and Prevention of Hair loss Comprising the Indicator Ingredient isolated from the Extract of Gynostemma Pentaphyllum
|
|
WO2020091512A1
|
|
Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
|
|
KR20200036755A
|
|
Novel Process For The Preparation Of (-)-Cibenzoline Succinate
|
|
WO2020067683A1
|
|
Novel process for the preparation of (+)-cibenzoline succinate
|
|
WO2020017901A1
|
|
Stable liquid pharmaceutical preparation
|
|
KR20190122580A
|
|
Method for controling fucosylation of glycoprotein
|
|
KR20190079530A
|
|
Method for diafiltration
|
|
WO2019151632A1
|
|
Binding molecule having neutralizing activity against middle east respiratory syndrome-coronavirus
|
|
KR20200060969A
|
|
Dosage Regimen For Treating Influenza Virus-Related Disease
|
|
KR20200058710A
|
|
Cosmetic composition comprising Pelargonium extract
|
|
WO2019074292A2
|
|
Expression cassette for production of high-expression and high-functionality target protein and use thereof
|
|
KR20190093107A
|
|
A binding molecules able to neutralize middle east respiratory-syndrome coronavirus
|
|
KR20190143246A
|
|
Novel linker compound and Site-Specific compounds of Antibody-Drug Conjugate Comprising the Same
|
|
KR101919113B1
|
|
Composition comprising Nelumbo Nucifera callus extract for reinforcing skin barrier
|
|
KR101898441B1
|
|
Cosmetic and Pharmaceutical Composition Containing Peptide with Epigenetic Regulatory Function
|
